@article{638a646018db47e49e7e38f25a1ef895,
title = "The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications",
abstract = "Objective: To quantify the effects of the Affordable Care Act Medicaid expansion on prescriptions for effective breast cancer hormonal therapies (tamoxifen and aromatase inhibitors) among Medicaid enrollees. Data Source/Study Setting: Medicaid State Drug Utilization Database (SDUD) 2011-2018, comprising the universe of outpatient prescription medications covered under the Medicaid program. Study Design: Differences-in-differences and event-study linear models compare population rates of tamoxifen and aromatase inhibitor (anastrozole, exemestane, and letrozole) use in expansion and nonexpansion states, controlling for population characteristics, state, and time. Principal Findings: Relative to nonexpansion states, Medicaid-financed hormonal therapy prescriptions increased by 27.2 per 100 000 nonelderly women in a state. This implies a 28.8 percent increase from the pre-expansion mean of 94.2 per 100 000 nonelderly women in expansion states. The event-study model reveals no evidence of differential pretrends in expansion and nonexpansion states and suggests use grew to 40 or more prescriptions per 100 000 nonelderly women 3-5 years postexpansion. Conclusions: Medicaid expansion may have had a meaningful impact on the ability of lower-income women to access effective hormonal therapies used to treat breast cancer.",
keywords = "Medicaid, breast cancer, differences-in-differences, prescription medications, public insurance",
author = "Maclean, {Johanna Catherine} and Halpern, {Michael T.} and Hill, {Steven C.} and Pesko, {Michael F.}",
note = "Funding Information: : Johanna Catherine Maclean and Michael F. Pesko were supported by a Research Scholar Grant – Insurance, RSGI‐16‐019‐01 – CHIPS, from the American Cancer Society. Michael Halpern was supported by TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership, Award Number U54 CA221704(5) from the National Cancer Institute. The views expressed in this paper are solely the authors' and do not reflect the views of the American Cancer Society, the Agency for Healthcare Research and Quality, the National Cancer Institute, the U.S. Department of Health and Human Services, the National Bureau of Economic Research, or the Institute for Labor Economics. Joint Acknowledgment/Disclosure Statement Funding Information: Joint Acknowledgment/Disclosure Statement: Johanna Catherine Maclean and Michael F. Pesko were supported by a Research Scholar Grant ? Insurance, RSGI-16-019-01 ? CHIPS, from the American Cancer Society. Michael Halpern was supported by TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership, Award Number U54 CA221704(5) from the National Cancer Institute. The views expressed in this paper are solely the authors' and do not reflect the views of the American Cancer Society, the Agency for Healthcare Research and Quality, the National Cancer Institute, the U.S. Department of Health and Human Services, the National Bureau of Economic Research, or the Institute for Labor Economics. Publisher Copyright: {\textcopyright} Health Research and Educational Trust",
year = "2020",
month = jun,
day = "1",
doi = "10.1111/1475-6773.13289",
language = "English (US)",
volume = "55",
pages = "399--410",
journal = "Health Services Research",
issn = "0017-9124",
publisher = "Wiley-Blackwell",
number = "3",
}